Monitoring for early detection of mesothelioma in patients with BAP1 mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of high-resolution dual energy computed tomographic imaging and noninvasive liquid biopsies for the early detection of mesotheliomas in individuals with BAP1 tumor predisposition syndrome. Participants, aged 30 and older, will undergo genetic testing to confirm the presence of BAP1 mutations and will be monitored over time through various assessments, including medical history reviews and physical exams. The study seeks to establish better surveillance protocols for those at high risk of developing mesothelioma and other cancers due to their genetic predisposition.

Why it matters

Who can join: the full rules

* ELIGIBILITY CRITERIA:

Inclusion Criteria for Genetic Testing

-Eligible participants include:

--Individuals with a history of any malignancy with known or suspected germline mutations involving BAP1

OR

--First- or second-degree relatives of patients (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)

* Age \>= 30 years.
* All participants must understand and be willing to sign a written informed consent document.

Inclusion Criteria for Surveillance

* Eligible participants include those who completed step 1 genetic testing with study-confirmed BAP1 or other germline TPDS mutation.
* Completed co-enrollment on protocol 06C0014, "Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies."

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: David S Schrump, M.D. — National Cancer Institute (NCI)
• Study coordinator: Rebecca B Alexander
• Email: rebecca.alexander@nih.gov
• Phone: (240) 781-4037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Partial pleurectomy to relieve symptoms from unresectable pleural mesothelioma.

  The team will try a limited partial pleurectomy and decortication to reduce chest symptoms and improve quality of life for people with epithelioid pleural mesothelioma that cannot be completely removed.

  Recruiting University of Chicago · Chicago, Illinois · NCT07126509

• Treatment with Sacituzumab Govitecan for Mesothelioma

  This study tests if a new treatment called sacituzumab govitecan can help people with mesothelioma who have already tried other therapies feel better and manage their disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06477419

• Oral treatment for early-stage mesothelioma in patients with BAP1 mutations

  This study is testing if a new oral treatment can help people with early-stage mesothelioma who have BAP1 mutations feel better and live longer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05960773

• Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy

  This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.

  Recruiting at 13 sites A2 Biotherapeutics Inc. · Gilbert, Arizona and 15 other locations · NCT04981119

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Two-part Phase 1/2 test of ODM-212 combined with other cancer treatments

  This trial tests the oral drug ODM-212, given alone or with approved medicines, to see if it helps adults with advanced mesothelioma, pancreatic cancer, or non-small cell lung cancer.

  Recruiting at 23 sites Phase 1/2 Orion Corporation, Orion Pharma · Los Angeles, California and 22 other locations · NCT07563738

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.